A US based emerging biopharma recognized that one of their anti-viral therapeutics being developed for a different indication might also help in the fight against the Coronavirus, COVID-19. Due to the emergency of the global pandemic they knew they had to react fast to meet the challenge but didn’t have the internal resources available.
Resources
webinar
The European Union is transforming its health technology assessment process with the introduction of the Joint Clinical Assessment (JCA) under…
blog
As regulatory landscapes evolve, staying ahead of new guidelines is crucial for life sciences companies. On May 29, 2024, the…
blog
Have you ever asked yourself how, as a patient, you would react if your physician proposed you to participate in…
blog
In the fast-paced world of biotech innovation, time is of the essence. For European biotech ventures eyeing entry into the…
